S. Collins

C. V. van Duijn, I. Zerr, A. Molesworth, 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Markers of A1 astrocytes stratify to molecular sub-types in sporadic Creutzfeldt–Jakob disease brain

A. Hill, C. Mclean, V. Lewis, 2020, Brain communications.

LGI1 antibody encephalopathy overlapping with sporadic Creutzfeldt-Jakob disease

C. Mclean, T. Sutherland, A. Boyd, 2016, Neurology: Neuroimmunology & Neuroinflammation.

Hyperekplexia as the presenting symptom of Creutzfeldt-Jakob disease.

V. Fung, M. Buckland, S. Ramanathan, 2015, Neurology. Clinical practice.

Australian sporadic CJD analysis supports endogenous determinants of molecular-clinical profiles

C. Masters, A. Hill, G. Klug, 2005, Neurology.

Novel prion protein insert mutation associated with prolonged neurodegenerative illness

C. Masters, A. Hill, C. Mclean, 2003, Neurology.

LGI 1 antibody encephalopathy overlapping with sporadic Creutzfeldt-Jakob disease

C. Mclean, T. Sutherland, A. Boyd, 2022 .

Gerstmann–Sträussler–Scheinker syndrome,fatal familial insomnia, and kuru: a review ofthese less common human transmissiblespongiform encephalopathies

C. Masters, C. Mclean, S. Collins, 2001, Journal of Clinical Neuroscience.

Recent developments in the transmissible spongiform encephalopathies: Implications for clinical practice

C. Masters, R. Cappai, S. Collins, 1996, Journal of Clinical Neuroscience.

Lyodura use and the risk of iatrogenic Creutzfeldt–Jakob disease in Australia

C. Masters, G. Klug, A. Boyd, 2004, The Medical journal of Australia.

Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study

K. Blennow, C. Rowe, R. Martins, 2022, Biomedicines.

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

A. Karch, J. Laplanche, I. Zerr, 2016, Molecular Neurobiology.

Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients

C. Masters, H. Wand, M. Law, 2020, Journal of Clinical Neuroscience.

Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease

A. G. Wedd, S. Collins, Marcus W. Brazier, 2014, Antioxidants.

Acute exposure to prion infection induces transient oxidative stress progressing to be cumulatively deleterious with chronic propagation in vitro.

C. Masters, C. Haigh, A. McGlade, 2011, Free radical biology & medicine.

Involvement of the 5‐lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106‐126

C. Masters, K. Beyreuther, R. Cappai, 2001, Journal of neuroscience research.

Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons

C. Masters, A. Hill, K. Beyreuther, 2001, Neurobiology of Disease.

Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?

C. Masters, L. Schonberger, A. McGlade, 2010, The Medical journal of Australia.

Novel prion protein gene mutation presenting with subacute PSP-like syndrome

C. Masters, C. Masters, D. Rowe, 2007, Neurology.

Gerstmann-Sträussler-Scheinker disease associated with a novel PRNP mutation ( V 176 G ) harbours a distinctive clinical and molecular-pathological profile

C. Masters, Qiao-Xin Li, C. Mclean, 2014 .

Unusual clinical and molecular-pathological profile of gerstmann-Sträussler-Scheinker disease associated with a novel PRNP mutation (V176G).

C. Masters, Qiao-Xin Li, R. Pamphlett, 2013, JAMA neurology.

Development of a neuroprotective antioxidant by a mix-and-match strategy -

C. Haigh, K. Barnham, S. Collins, 2013 .

Correlative studies support lipid peroxidation is linked to PrPres propagation as an early primary pathogenic event in prion disease

C. Masters, A. Hill, R. Cappai, 2006, Brain Research Bulletin.

The effects of prion protein expression on metal metabolism

David R. Brown, K. Ragnarsdóttir, S. Collins, 2009, Molecular and Cellular Neuroscience.

Genetic prion disease–associated myelodysplasia and SIADH in siblings

Y. Berman, A. McGlade, M. Buckland, 2011, European journal of neurology.

Near-infrared fluorescence imaging of apoptotic neuronal cell death in a live animal model of prion disease.

C. Masters, C. Haigh, B. Roberts, 2010, ACS chemical neuroscience.

Transmissible spongiform encephalopathies in Australia.

C. Masters, A. Boyd, V. Lewis, 2001, Communicable diseases intelligence quarterly report.

Extended period of asymptomatic prion disease after low dose inoculation: Assessment of detection methods and implications for infection control

C. Masters, A. Hill, G. Klug, 2005, Neurobiology of Disease.

PrPSc Oligomerization Appears Dynamic, Quickly Engendering Inherent M1000 Acute Synaptotoxicity.

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2020, Biophysical journal.

The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases

B. Caughey, W. Schulz-Schaeffer, I. Zerr, 2016, Nature Protocols.

Neutron reflectometry studies define prion protein N-terminal peptide membrane binding.

C. Haigh, Martin P Boland, S. Collins, 2014, Biophysical journal.

Microwave Synthesis of Prion Protein Fragments up to 111 Amino Acids in Length Generates Biologically Active Peptides

A. Hill, C. Haigh, J. Karas, 2011, International Journal of Peptide Research and Therapeutics.

C. Masters, A. Hill, C. Haigh, 2009, Cell Research.

Mouse-adapted sporadic human Creutzfeldt-Jakob disease prions propagate in cell culture.

C. Masters, A. Hill, R. Cappai, 2008, The international journal of biochemistry & cell biology.

Creutzfeldt-Jakob disease: diagnostic utility of 14–3–3 protein immunodetection in cerebrospinal fluid

C. McLean, C. Masters, M. Gonzales, 2000, Journal of Clinical Neuroscience.

Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction

S. Collins, E. Athan, A. Koehler, 2013, The Medical journal of Australia.

Creutzfeldt-Jakob disease: Australian surveillance update to March 2007.

C. Masters, G. Klug, A. Boyd, 2007, Communicable diseases intelligence quarterly report.

Creutzfeldt-Jakob disease surveillance in Australia January 1970 to December 2003.

C. Masters, G. Klug, A. Boyd, 2004, Communicable diseases intelligence quarterly report.

Creutzfeldt‐Jakob disease cluster in an Australian rural city

J. Kaldor, C. Masters, C. Mclean, 2002, Annals of neurology.

Recent advances in the pre-mortem diagnosis of Creutzfeldt-Jakob disease

C. Masters, C. Mclean, M. Gonzales, 2000, Journal of Clinical Neuroscience.

Surveillance of Creutzfeldt-Jakob disease in Australia: update to December 2010.

C. Masters, A. McGlade, G. Klug, 2011, Communicable diseases intelligence quarterly report.

Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?

C. Masters, G. Klug, A. Boyd, 2011 .

Surveillance of Creutzfeldt-Jakob disease in Australia: 2008.

C. Masters, A. McGlade, G. Klug, 2008, Communicable diseases intelligence quarterly report.

Respiratory Chain Encephalomyopathies: A Diagnostic Classification

U. Walker, S. Collins, E. Byrne, 1996, European Neurology.

Prion protein “gamma-cleavage”: characterizing a novel endoproteolytic processing event

N. Hooper, P. Crouch, G. Klug, 2016, Cellular and Molecular Life Sciences.

Chronic wasting disease

S. Collins, 2007 .

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease

B. Caughey, I. Zerr, M. Geschwind, 2021, The Lancet Neurology.

Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD

H. Butzkueven, F. Gaillard, V. Lewis, 2022, BMJ Neurology Open.

Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2019, PLoS pathogens.

Are mitochondrial DNA deletions causative in chronic progressive external ophthalmoplegia patients?

S. Collins, E. Byrne, X. Dennett, 1997, Journal of Clinical Neuroscience.

A 2-Substituted 8-Hydroxyquinoline Stimulates Neural Stem Cell Proliferation by Modulating ROS Signalling

C. Haigh, S. Collins, S. Drew, 2016, Cell Biochemistry and Biophysics.

The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106–126: Comparative use of manual Boc and Fmoc chemistry

C. Masters, R. Cappai, C. Barrow, 2006, Letters in Peptide Science.

Prion protein cleavage fragments regulate adult neural stem cell quiescence through redox modulation of mitochondrial fission and SOD2 expression

C. Haigh, S. Collins, B. Groveman, 2018, Cellular and Molecular Life Sciences.

Simplified Murine 3D Neuronal Cultures for Investigating Neuronal Activity and Neurodegeneration

C. Haigh, S. Collins, 2017, Cell Biochemistry and Biophysics.

Endoproteolytic cleavage as a molecular switch regulating and diversifying prion protein function

C. Haigh, S. Collins, 2016, Neural regeneration research.

Association of the MELAS m.3243A>G mutation with myositis and the superiority of urine over muscle, blood and hair for mutation detection

S. Collins, J. Chin, P. Mckelvie, 2009, Journal of Clinical Neuroscience.

Iatrogenic and zoonotic Creutzfeldt–Jakob disease: the Australian perspective

C. Masters, S. Collins, 1996, The Medical journal of Australia.

Quantifying prion disease penetrance using large population control cohorts

Patrick F. Sullivan, Karen L. Mohlke, M. Arfan Ikram, 2016, Science Translational Medicine.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

A. Karch, I. Zerr, I. Santana, 2018, Molecular Neurobiology.

Novel single base pair COX III subunit deletion of mitochondrial DNA associated with rhabdomyolysis

D. Kirby, S. Collins, J. Chin, 2011, Journal of Clinical Neuroscience.

MENINGOENCEPHALOMYELITIS WITH VASCULITIS DUE TO VARICELLA ZOSTER VIRUS: A CASE REPORT AND REVIEW OF THE LITERATURE

D. Thyagarajan, S. Collins, E. Byrne, 2002, Pathology.

Cerebrospinal fluid neurofilament light and cerebral atrophy in younger‐onset dementia and primary psychiatric disorders

C. Masters, M. Walterfang, D. Velakoulis, 2022, Internal medicine journal.

Variant Creutzfeldt-Jakob disease and the potential for its accidental transmission following surgery with contaminated instruments: the risk of transmission in Australia.

S. Collins, I. Ramasamy, F. Brooke, 2003, Folia neuropathologica.

MEK1 transduces the prion protein N2 fragment antioxidant effects

C. Haigh, A. McGlade, S. Collins, 2015, Cellular and Molecular Life Sciences.

Dominant roles of the polybasic proline motif and copper in the PrP23-89-mediated stress protection response

C. Masters, C. Haigh, Martin P Boland, 2009, Journal of Cell Science.

Contrasting histochemical features of various mitochondrial syndromes

S. Collins, E. Byrne, X. Dennett, 1995, Acta neurologica Scandinavica.

Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

K. Blennow, C. Rowe, R. Martins, 2022, Alzheimer's & dementia.

Oxidation of Iron under Physiologically Relevant Conditions in Biological Fluids from Healthy and Alzheimer's Disease Subjects.

A. Bush, J. Duce, Qiao-Xin Li, 2017, ACS chemical neuroscience.

Increased Proportions of C1 Truncated Prion Protein Protect Against Cellular M1000 Prion Infection

C. Masters, A. Hill, C. Haigh, 2009, Journal of neuropathology and experimental neurology.

Title Ultrasensitive human prion detection in cerebrospinal fluid by real-timequaking-induced conversion

H. Mizusawa, M. Yamada, K. Satoh, 2017 .

Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia

M. Walterfang, C. Masters, C. Malpas, 2021, Journal of the Neurological Sciences.

Transmissible spongiform encephalopathies

C. Masters, S. Collins, V. Lawson, 2004, The Lancet.

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

R. Martins, C. Masters, S. Burnham, 2020, Alzheimer's Research & Therapy.

Metal attenuating therapies in neurodegenerative disease

David R. Brown, A. G. Wedd, S. Collins, 2011, Expert review of neurotherapeutics.

Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity

G. Guillemin, U. Habiba, U. Adhikari, 2021, Frontiers in Immunology.

Surveillance for Creutzfeldt-Jakob disease in Australia: update to December 2012.

C. Masters, C. Mclean, G. Klug, 2013, Communicable diseases intelligence quarterly report.

Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study

C. Masters, M. Law, A. Boyd, 1999, The Lancet.

Psychosocial and neuropsychological outcomes in two high-functioning males 20 years after traumatic brain injury

M. Cook, Simon J. Vogrin, S. Bowden, 1999 .

Mitochondrial genome distribution in histochemically cytochrome c oxidase-negative muscle fibres in patients with a mixture of deleted and wild type mitochondrial DNA.

S. Marzuki, S. Collins, E. Byrne, 1991, Biochimica et biophysica acta.

Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease

A. Karch, D. Varges, I. Zerr, 2015, Molecular Neurobiology.

The cellular prion protein beyond prion diseases.

F. Fallarino, S. Mouillet-Richard, V. Lewis, 2020, Swiss medical weekly.

A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk

A. Hofman, A. Uitterlinden, F. Rivadeneira, 2015, PloS one.

Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada

A. Aguzzi, H. Budka, C. V. van Duijn, 2005, Neurology.

The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro

Qiao-Xin Li, C. Haigh, T. Ryan, 2015, Stem Cell Research & Therapy.

Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology

R. Martins, C. Masters, D. Ames, 2015, Alzheimer's Research & Therapy.

Ascertainment bias causes false signal of anticipation in genetic prion disease.

E. Minikel, A. Karch, S. Mead, 2014, American journal of human genetics.

McArdle's disease resembling an inflammatory myopathy

S. Collins, E. Byrne, P. Mckelvie, 1998, Journal of Clinical Neuroscience.

Genetic prion disease: the EUROCJD experience

A. Aguzzi, H. Budka, C. V. van Duijn, 2005, Human Genetics.

Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease

C. Begue, R. G. Will, J. P. Brandel, 2009, Brain : a journal of neurology.

Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity.

K. Beyreuther, R. Cappai, C. Masters, 1999, The American journal of pathology.

Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.

J Mackenzie, H. Budka, G. Jansen, 2006, Brain : a journal of neurology.

CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt–Jakob disease diagnosis while transitioning to next generation diagnostics

C. Masters, Qiao-Xin Li, J. Doecke, 2018, Journal of Clinical Neuroscience.

Explorer Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease

G. Jansen, K. Kallenberg, P. Smith, 2016 .

A case of myelopathy, myopathy, peripheral neuropathy and subcortical grey matter degeneration associated with recessive compound heterozygous POLG1 mutations

D. Thorburn, S. Collins, J. Chin, 2012, Neuromuscular Disorders.

Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion

Steven J Collins, Masahito Yamada, H. Mizusawa, 2011, Nature Medicine.

Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study

C. Duijn, A. Aguzzi, H. Budka, 2020, The Lancet Neurology.

Anionic Phospholipid Interactions of the Prion Protein N Terminus Are Minimally Perturbing and Not Driven Solely by the Octapeptide Repeat Domain*

C. Masters, A. Hill, D. Tew, 2010, The Journal of Biological Chemistry.

NOTES Different Mechanisms Account fortheRelative Resistance of KG-1andHL-60CellLines toRetrovirus Infection

S. Collins, 1988 .

Overview and recent advances in neuropathology. Part 2: Neurodegeneration.

C. Masters, A. Hill, J. Kril, 2011, Pathology.

Molecular Subtyping of PrPres in Human Sporadic CJD Brain Tissue.

G. Klug, V. Lewis, S. Collins, 2017, Methods in molecular biology.

Prion subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level disparity

C. Masters, A. Hill, C. Haigh, 2012, Molecular Neurodegeneration.

Molecular typing of PrPres in human sporadic CJD brain tissue.

A. Hill, G. Klug, V. Lewis, 2008, Methods in molecular biology.

Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2018, PLoS pathogens.

In vivo prion models and the disconnection between transmissibility and neurotoxicity

P. Adlard, D. Finkelstein, V. Lewis, 2017, Ageing Research Reviews.

Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies.

A. Aguzzi, H. Budka, C. V. van Duijn, 2004, Brain : a journal of neurology.

Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease

Qiao-Xin Li, J. Doecke, A. McGlade, 2023, Frontiers in Neurology.

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

A. Karch, J. Laplanche, I. Zerr, 2016, Molecular Neurobiology.

The Three Glycotypes in the London Classification System of Sporadic Creutzfeldt-Jakob Disease Differ in Disease Duration

D. Velakoulis, Qiao-Xin Li, V. Lewis, 2021, Molecular Neurobiology.

Creutzfeldt–Jakob disease in Australia 1970–1999

J. Kaldor, C. Masters, M. Law, 2002, Neurology.

Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease

I. Zerr, F. Brett, F. Llorens, 2020, Biomolecules.

Cerebrospinal fluid real‐time quaking‐induced conversion is a robust and reliable test for sporadic creutzfeldt–jakob disease: An international study

P. Cras, I. Zerr, F. Tagliavini, 2016, Annals of neurology.

Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease

H. Budka, J. Laplanche, H. Bernheimer, 2000, Neurology.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings

K. Blennow, C. Masters, S. Berkovic, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease

Victoria J. Williams, K. Blennow, E. Minikel, 2019, BMC Medicine.

14-3-3 protein detection and sporadic CJD: the status quo serves well while awaiting progress

C. Masters, A. McGlade, G. Klug, 2010, Journal of Neurology, Neurosurgery & Psychiatry.

Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study

C. Duyckaerts, F. Tagliavini, L. Schonberger, 2018, Acta Neuropathologica Communications.

Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993–2002

H. Budka, G. Jansen, C. V. van Duijn, 2006, BMC public health.

Age at onset in genetic prion disease and the design of preventive clinical trials.

E. Minikel, S. Mead, J. Laplanche, 2019, Neurology.

Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease.

C. Masters, K. Byron, C. Harper, 2000, Archives of neurology.

Age of onset in genetic prion disease and the design of preventive clinical trials

E. Minikel, S. Mead, J. Laplanche, 2018, bioRxiv.

Erratum to: Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020.

C. Masters, A. McGlade, G. Klug, 2021, Communicable diseases intelligence.

Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster.

J. Kaldor, C. Masters, H. Wand, 2009, Brain : a journal of neurology.

The Prion Protein N1 and N2 Cleavage Fragments Bind to Phosphatidylserine and Phosphatidic Acid; Relevance to Stress-Protection Responses

C. Haigh, S. Collins, S. Drew, 2015, PloS one.

Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction

S. Collins, E. Athan, A. Koehler, 2013, The Medical journal of Australia.

Intensity of human prion disease surveillance predicts observed disease incidence

C. Masters, H. Budka, G. Jansen, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

Surveillance of Creutzfeldt-Jakob disease in Australia: update to December 2011.

C. Masters, A. McGlade, G. Klug, 2012, Communicable diseases intelligence quarterly report.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021.

C. Masters, A. McGlade, G. Klug, 2022, Communicable diseases intelligence.

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Joanne S. Robertson, C. Rowe, R. Martins, 2021, Journal of Alzheimer's disease reports.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Joanne S. Robertson, C. Rowe, R. Martins, 2015, Journal of Alzheimer's disease : JAD.

Structural biology of prions.

Steven J Collins, Roberto Cappai, R. Cappai, 2004, Contributions to microbiology.

Sporadic Creutzfeldt–Jakob disease presenting as spastic paraparesis

N. Simon, M. Buckland, S. Collins, 2013, European journal of neurology.

11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease

C. Rowe, C. Masters, V. Villemagne, 2009, Journal of Neurology, Neurosurgery & Psychiatry.

Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study

C. Duyckaerts, F. Tagliavini, L. Schonberger, 2018, Acta neuropathologica communications.

A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists?

C. Masters, M. Walterfang, D. Velakoulis, 2020, The Australian and New Zealand journal of psychiatry.

Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease.

S. Collins, I Ramasamy, M Law, 2003, The Lancet. Infectious diseases.

For personal use. Only reproduce with permission The Lancet Publishing Group. Yet another spinocerebellar ataxia—will it ever end?

Andrew F. Hill, Victoria Lewis, A Boyd, 2002 .

Therapeutic interventions ameliorating prion disease

C. Masters, S. Collins, Marcus W. Brazier, 2009, Expert review of anti-infective therapy.

Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates.

C. Masters, A. Hill, Mitch Shambrook, 2015, Glycobiology.

Prion protein glycosylation

A. Hill, S. Collins, V. Lawson, 2005, Journal of neurochemistry.

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer’s Disease

Blaine R. Roberts, N. Corcoran, C. Hovens, 2018, Neurotherapeutics.

"To Treat or not To Treat": Informing the Decision for Disease-Modifying Therapy in Late-Stage Alzheimer's Disease.

P. Desmond, N. L. Jenkins, G. McColl, 2019, Journal of Alzheimer's Disease.

Ethical Issues in the Treatment of Late-Stage Alzheimer’s Disease

P. Desmond, N. L. Jenkins, G. McColl, 2018, Journal of Alzheimer's disease : JAD.

Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective.

S. Collins, J. Chin, R. Marotta, 2014, Mitochondrion.

Plasma p‐tau181/Aβ1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ1‐42 and future cognitive decline

C. Rowe, R. Martins, C. Masters, 2022, medRxiv.

No evidence for prion protein gene locus multiplication in Creutzfeldt-Jakob disease

C. Duijn, C. Masters, B. Oostra, 2010, Neuroscience Letters.

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes

Sterling C. Johnson, M. Albert, A. Fagan, 2019, Neurology.

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

H. Vanderstichele, R. Martins, C. Masters, 2021, Alzheimer's research & therapy.

Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study

C. Rowe, R. Martins, C. Masters, 2019, The Journal of Prevention of Alzheimer's Disease.

Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.

Jamie R. Kutasovic, S. Lakhani, F. Al-Ejeh, 2019, JCI insight.

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

K. Blennow, C. Rowe, R. Martins, 2020, Alzheimer's & dementia.

Cellular Prion Protein Expression Is Not Regulated by the Alzheimer's Amyloid Precursor Protein Intracellular Domain

N. Hooper, J. Manson, V. Lewis, 2012, PloS one.

Comparative Utility of Manual versus Automated Segmentation of Hippocampus and Entorhinal Cortex Volumes in a Memory Clinic Sample.

Yi Leng Fung, Kelly E T Ng, Simon J Vogrin, 2019, Journal of Alzheimer's disease : JAD.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020.

C. Masters, A. McGlade, C. Mclean, 2021, Communicable diseases intelligence.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2019.

C. Masters, A. McGlade, C. Mclean, 2019, Communicable diseases intelligence.

Creutzfeldt-Jakob disease surveillance in Australia: update to December 2015.

C. Masters, C. Mclean, G. Klug, 2016, Communicable diseases intelligence quarterly report.

Late-adult onset Leigh syndrome

D. Thorburn, S. Collins, J. Chin, 2012, Journal of Clinical Neuroscience.

Generating recombinant C-terminal prion protein fragments of exact native sequence

A. Hill, S. Collins, V. Johanssen, 2012, Neurochemistry International.

Long-term screening for primary mitochondrial DNA variants associated with Leber Hereditary Optic Neuropathy: incidence, penetrance and clinical features.

S. Collins, J. Chin, N. Shuey, 2020, Mitochondrion.

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.

N. Corcoran, C. Hovens, M. Saling, 2016, Journal of Alzheimer's disease : JAD.

Diagnostic screening of mitochondrial DNA mutations in Australian adults 1990–2001

A. Quigley, S. Collins, E. Byrne, 2004, Internal medicine journal.

Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels

C. Rowe, R. Martins, C. Masters, 2022, Neurobiology of Aging.

Chronic progressive external ophthalmoplegia in patients with large heteroplasmic mitochondrial DNA deletions: an immunocytochemical study

S. Marzuki, S. Collins, E. Byrne, 2004, Acta Neuropathologica.

Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery

C. Rowe, C. Masters, N. Yassi, 2022, Stroke.

Optical Imaging Detects Apoptosis in the Brain and Peripheral Organs of Prion-Infected Mice

C. Masters, C. Haigh, K. Barnham, 2011, Journal of neuropathology and experimental neurology.

Surveillance of Creutzfeldt-Jakob disease in Australia , 2011 Annual reports Results Australian National Creutzfeldt-Jakob Disease

C. Masters, A. McGlade, G. Klug, 2012 .

The Prion Protein Preference of Sporadic Creutzfeldt-Jakob Disease Subtypes*

C. Masters, A. Hill, G. Klug, 2012, The Journal of Biological Chemistry.

Glycosaminoglycan Sulphation Affects the Seeded Misfolding of a Mutant Prion Protein

C. Masters, A. Hill, D. Hoke, 2010, PloS one.

Creutzfeldt-Jakob disease: Australian surveillance update to December 2005.

C. Masters, G. Klug, A. Boyd, 2006, Communicable diseases intelligence quarterly report.

Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders.

K. Blennow, C. Masters, S. Berkovic, 2023, Acta neuropsychiatrica.

Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response

C. Masters, M. Walterfang, D. Velakoulis, 2019, The Australian and New Zealand journal of psychiatry.

CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias

C. Masters, R. Holsinger, A. Boyd, 2006, Neurology.

Increased β‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects

C. Masters, G. Evin, R. Holsinger, 2004, Annals of neurology.

Biochemical and molecular investigation of mitochondrial disease: an illustrative case showing the value of a multifaceted approach.

D. Thyagarajan, S. Marzuki, S. Collins, 1991, Australian and New Zealand journal of medicine.

Diverse fibrillar peptides directly bind the Alzheimer’s amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation

C. Masters, G. Multhaup, K. Beyreuther, 2003, Brain Research.

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.

H. Vanderstichele, R. Martins, C. Masters, 2017, Journal of Alzheimer's disease : JAD.

Prion disease in Indigenous Australians

C. Masters, P. Panegyres, G. Klug, 2020, Internal medicine journal.

Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model

C. Masters, A. Hill, V. Lewis, 2002, Annals of neurology.

Surveillance of Creutzfeldt-Jakob disease in Australia: 2010 update.

C. Masters, A. McGlade, G. Klug, 2010, Communicable diseases intelligence quarterly report.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2018.

C. Masters, C. Mclean, G. Klug, 2019, Communicable diseases intelligence.

Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016.

C. Masters, C. Mclean, G. Klug, 2018, Communicable diseases intelligence.

Ethical considerations in presymptomatic testing for variant CJD

C. Masters, J. Savulescu, M. Delatycki, 2005, Journal of Medical Ethics.

Agreement Between Automated and Manual MRI Volumetry in Alzheimer's Disease: A Systematic Review and Meta‐Analysis

M. Cheung, Simon J. Vogrin, S. Bowden, 2021, Journal of magnetic resonance imaging : JMRI.

Microwave Synthesis of Prion Protein Fragments up to 111 Amino Acids in Length Generates Biologically Active Peptides

A. Hill, C. Haigh, J. Karas, 2012, International Journal of Peptide Research and Therapeutics.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

A. Karch, I. Zerr, I. Santana, 2018, Molecular Neurobiology.

Immunotherapeutic approaches in prion disease: progress, challenges and potential directions.

S. Collins, Anthony R. White, Marcus W. Brazier, 2013, Therapeutic delivery.

Genome-wide association study identifies risk variants for sporadic Creutzfeldt-Jakob disease in STX6 and GAL3ST1

A. Aguzzi, H. Budka, G. Jansen, 2020, medRxiv.

S u rgical treatment and risk of sporadic Cre u t z f e l d t - J a k o b disease: a case-control study

J. Kaldor, C. Masters, A. Boyd, 1999 .

Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease

C. Rowe, R. Martins, C. Masters, 2020, Neuroscience Letters.

Tailored behavioural tests reveal early and progressive cognitive deficits in M1000 prion disease

J. Kim, P. Adlard, D. Finkelstein, 2023, Neurobiology of Disease.

Left insular stroke is associated with adverse cardiac outcome

C. Masters, R. Holsinger, A. Boyd, 2006, Neurology.

Iatrogenic Creutzfeldt–Jakob disease at the millennium

L. McShane, I. Zerr, T. Sato, 2000, Neurology.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2022.

A. McGlade, G. Klug, V. Lewis, 2023, Communicable diseases intelligence.

Creutzfeldt-Jakob disease surveillance in Australia, update to December 2013.

G. Klug, A. Boyd, C. Stehmann, 2014, Communicable diseases intelligence quarterly report.

MRI lesion profiles in sporadic Creutzfeldt–Jakob disease

D. Galanaud, G. Jansen, K. Kallenberg, 2009, Neurology.

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

R. Martins, C. Masters, S. Burnham, 2020, Alzheimer's Research & Therapy.

Communicable Diseases Intelligence 2022-Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021

C. Masters, A. McGlade, G. Klug, 2022 .

Creutzfeldt–Jakob disease surveillance in Australia: update to December 2017

C. Masters, V. Lewis, C. Stehmann, 2019, Communicable diseases intelligence.

Prion protein “gamma-cleavage”: characterizing a novel endoproteolytic processing event

N. Hooper, P. Crouch, G. Klug, 2015, Cellular and Molecular Life Sciences.

Increased Proportions of C1 Truncated Prion Protein Protect Against Cellular M1000 Prion Infection

C. Masters, A. Hill, C. Haigh, 2009, Journal of neuropathology and experimental neurology.

RT-QuIC Assays in Humans … and Animals.

S. Collins, S. Sarros, 2016, Food safety.